All In MedTech

FDA Clearance Tracker · K183313

EUROIMMUN Anti-tissue Transglutaminase ELISA (IgA), EUROIMMUN Anti-tissue Transglutaminase ELISA (IgG)

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Feb 28, 2019 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Feb 28, 2019

Substantially Equivalent

Time to decision

91 days

Received Nov 29, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K183313
Device name
EUROIMMUN Anti-tissue Transglutaminase ELISA (IgA), EUROIMMUN Anti-tissue Transglutaminase ELISA (IgG)
Applicant location
Mountain Lakes, NJ
Received
Nov 29, 2018
Decided
Feb 28, 2019
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 866.5660

Every decision under product code MVM

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MVM. The earliest in FDA's data is K982366, decided Aug 27, 1998.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

  • FDA database record for K183313
  • The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Euroimmun Us, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.